Literature DB >> 11314772

The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

M Gerlach1, A Y Xiao, W Kuhn, R Lehnfeld, P Waldmeier, K H Sontag, P Riederer.   

Abstract

Inhibition of catechol catechol-O-methyltransferase (COMT) in the brains of subjects treated with L-DOPA (L-3,4-dihydroxylphenylalanine) and an aromatic amino acid decarboxylase (AADC) inhibitor is suggested to cause an increase of L-DOPA, which might lead to oxidative damage through enhanced formation of free radicals. To investigate this hypothesis, the acute effects of two doses of the systemically administered COMT inhibitors entacapone (peripheral) and tolcapone (peripheral and central) on the extracellular formation of hydroxyl radicals in vivo following treatment with L-DOPA and the AADC inhibitor carbidopa were examined. The formation of extracellular hydroxyl radicals were determined by the measurement of 2,3-dihydroxybenzoic acid (2,3-DHBA), a reaction product of hydroxyl radicals with sodium salicylate, using microdialysis in the striatum of anesthetised rats. The COMT inhibitors were administered together with 50 mg/kg i.p. carbidopa as 5% gum arabic suspensions intraperitoneally (i.p.) at doses of 0, 1.0, and 10 mg/kg body weight to a total of 36 male HAN-Wistars rats. L-DOPA was injected i.p. 40 min after drugs of interest. Microdialysis samples were collected every 20 min for 400 min at a perfusion rate of 1 microl/min. Systemically administered 10 mg/kg tolcapone, but not entacapone, induced an increase in hydroxyl radical formation in the striatum of anesthetised rats following treatment with L-DOPA/carbidopa. The increase in hydroxyl radical formation was reflected by higher extracellular concentrations of the hydroxylate product of salicylate, 2,3-DHBA, peaking at 192% of baseline at the end of the observation period. Similar results were also found using the AUC (area under the curve) value estimated for the observation period. We conclude that the increase in hydroxyl radical formation is likely to result from an increased rate of monoamine oxidase-mediated and non-enzymatic (autoxidation) dopamine metabolism following increased central availability caused by reduction in COMT-mediated metabolism. We cannot, however, exclude the possibility that hydroxyl radicals are produced by tolcapone as a result of uncoupling mitochondrial oxidative phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314772     DOI: 10.1007/s007020170087

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  23 in total

1.  Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Authors:  V V Myllylä; K A Sotaniemi; P Hakulinen; O Mäki-Ikola; E H Heinonen
Journal:  Acta Neurol Scand       Date:  1997-04       Impact factor: 3.209

2.  Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

Authors:  E Acquas; E Carboni; R H de Ree; M Da Prada; G Di Chiara
Journal:  J Neurochem       Date:  1992-07       Impact factor: 5.372

3.  Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

Authors:  W Staffen; A Mair; J Unterrainer; E Trinka; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

4.  Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.

Authors:  P T Männistö; P Tuomainen; R K Tuominen
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

5.  Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.

Authors:  T Brannan; A Prikhojan; M D Yahr
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion.

Authors:  D M Camp; D A Loeffler; P A LeWitt
Journal:  J Neurochem       Date:  2000-03       Impact factor: 5.372

7.  Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

Authors:  E Nissinen; P Kaheinen; K E Penttilä; J Kaivola; I B Lindén
Journal:  Eur J Pharmacol       Date:  1997-12-11       Impact factor: 4.432

8.  Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein.

Authors:  T Karhunen; C Tilgmann; I Ulmanen; P Panula
Journal:  Neurosci Lett       Date:  1995-02-24       Impact factor: 3.046

9.  Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system.

Authors:  A Kastner; P Anglade; C Bounaix; P Damier; F Javoy-Agid; N Bromet; Y Agid; E C Hirsch
Journal:  Neuroscience       Date:  1994-09       Impact factor: 3.590

10.  Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.

Authors:  A Napolitano; G Zürcher; M Da Prada
Journal:  Eur J Pharmacol       Date:  1995-02-06       Impact factor: 4.432

View more
  3 in total

1.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

2.  Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

Authors:  Manfred Gerlach; Maarten van den Buuse; Charles Blaha; Dirk Bremen; Peter Riederer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-20       Impact factor: 3.000

3.  Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.

Authors:  Markus M Forsberg; Risto O Juvonen; Petra Helisalmi; Jukka Leppänen; Joseph A Gogos; Maria Karayiorgou; Pekka T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-17       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.